Your WELIREG
(belzutifan) Treatment

Your treatment patient diary

This diary booklet has been developed to support patients that have been prescribed WELIREG.
Use it to learn more about your treatment, how it works and what to look out for. Document how you feel, including any side effects, and keep a note of any questions you may have for your healthcare team.

Get the diary (PDF)

Your treatment

What is WELIREG

WELIREG is a once-daily oral medicine used to treat adults with von Hippel-Lindau disease who need treatment for a type of kidney cancer called renal cell carcinoma, tumours in the brain and spinal cord called central nervous system hemangioblastomas, or a type of pancreatic cancer called pancreatic neuroendocrine tumours, and for whom surgery or other local procedures are unsuitable or undesirable.

The recommended dose of WELIREG is:

Three 40-mg tablets (120 mg) taken by mouth at the same time each day.
You may take WELIREG with or without food.

Not actual size shown.
For illustration purposes only.

Things to keep in mind while taking WELIREG

Take WELIREG exactly as the doctor prescribes.

Take your prescribed dose once a day, at the same time each day. Your doctor may change your dose if needed.

Do not break, crush, or chew the tablet – swallow the tablet whole.

What to look out for

Tell your healthcare professional immediately if you notice any side effects (do not wait until your next appointment). Reporting side effects early is important to prevent them from becoming more serious or having to stop treatment. Do not try to diagnose or treat side effects yourself.

Side effects of WELIREG

Very common (may affect more than 1 in 10 people):

Low red blood cells
(Anaemia)

Feeling tired

Feeling dizzy

Have difficulty breathing

Feeling sick (nausea)

Weight gain

Common (may affect up to 1 in 10 people):

• Abnormally low oxygen levels in the blood

Serious side effects:

• WELIREG may decrease your red blood cell level.
  Common symptoms include shortness of breath, fatigue, dizziness and pale skin.
• WELIREG may decrease the oxygen level in your blood. Common symptoms include shortness of breath, increased heart rate, rapid breathing and feeling anxious or restless. Low oxygen levels may require you to stop treatment with WELIREG, receive oxygen therapy or be hospitalised. Contact your doctor immediately if you develop any of the following symptoms: bluish discolouration of the skin around your mouth, inability to speak in full sentences without catching your breath, unusual tiredness and confusion. In light of this risk, you should stop smoking while taking WELIREG.

---

Family planning

If you or your partner become pregnant while using WELIREG, talk to your doctor straight away. This also applies if you are a man whose female partner could get pregnant.

Your doctor will carry out a pregnancy test before you start taking the medicine. WELIREG may harm your unborn baby and cause a miscarriage. This means:

• You should not become pregnant while taking WELIREG
• You should not take WELIREG if you are pregnant

Birth control methods (contraception) that contain hormones (e.g. birth control pills, injections, transdermal system patches) may not work as well during treatment with WELIREG. You and your partner should use an effective form of non-hormonal contraception (e.g. condoms) during treatment with WELIREG and for 1 week after your last dose.

Where can I go for further support?

Your healthcare team should have provided you with a Patient Information Leaflet and Patient Alert Card to help you understand more about your treatment and identify any side effects you may experience. Ensure you read these materials and carry your Patient Alert Card with you at all times. This card is important to have in emergencies and when meeting other/new healthcare professionals.

You can also download the WELIREG treatment diary to use digitally or ask your healthcare professional for a printed version. You can use it to learn more about your treatment, how it works and what to look out for, document how you feel, including any side effects, and keep a note of any questions you may have for your healthcare team.

For more information and support with living with VHL,
visit the VHL UK/Ireland Charity website:
www.vhl-uk-ireland.org.

References

WELIREG (belzutifan). Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/files/pil.14126.pdf.